Patents Examined by M. Franco Salvoza
  • Patent number: 10039823
    Abstract: The present invention provides a human dose of an immunogenic composition comprising an antigen or antigenic preparation, in combination with an adjuvant which adjuvant comprises an immunologically active saponin fraction derived from the bark of Quillaja Saponaria Molina presented in the form of a liposome and a lipopolysaccharide wherein said saponin fraction and said lipopolysaccharide are both present in said human dose at a level of below 30 ?g. The present invention further provides an adjuvant composition in a human dose suitable volume comprising between 1 and 30 ?g of a lipopolysaccharide and between 1 and 30 ?g of an immunologically active saponin fraction presented in the form of a liposome.
    Type: Grant
    Filed: February 3, 2011
    Date of Patent: August 7, 2018
    Assignee: GlaxoSmithKline Biologicals, S.A.
    Inventor: Pierre Vandepapeliere
  • Patent number: 9925257
    Abstract: The present invention relates to a new vaccine delivery system. In particular, the present invention includes compositions and methods of integrally transformed non-pathogenic, commensal bacteria that can express a nucleic acid molecule of a foreign polypeptide, wherein the nucleic acid molecule that encodes the foreign polypeptide is stably integrated into genomic DNA of the bacteria. The foreign polypeptide includes a vaccine antigen that elicits an immunogenic response, an inhibitor of a pathogen, or an immune booster or modulator.
    Type: Grant
    Filed: January 23, 2015
    Date of Patent: March 27, 2018
    Assignee: Forsyth Dental Infirmary for Children
    Inventors: Antonio Campos-Neto, Mark Cayabyab, Margaret Duncan
  • Patent number: 9884108
    Abstract: The present invention relates to a new vaccine delivery system. In particular, the present invention includes compositions and methods of integrally transformed non-pathogenic, commensal bacteria that can express a nucleic acid molecule of a foreign polypeptide, wherein the nucleic acid molecule that encodes the foreign polypeptide is stably integrated into genomic DNA of the bacteria. The foreign polypeptide includes a vaccine antigen that elicits an immunogenic response, an inhibitor of a pathogen, or an immune booster or modulator.
    Type: Grant
    Filed: June 3, 2016
    Date of Patent: February 6, 2018
    Assignee: Forsyth Dental Infirmary for Children
    Inventors: Antonio Campos-Neto, Mark Cayabyab, Margaret Duncan
  • Patent number: 9878002
    Abstract: This disclosure describes methods and compositions that involve endogenous retrovirus proteins as diagnostic markers and/or therapeutic agents. The detection of endogenous retrovirus envelope proteins on a cell surface can indicate early neoplasticity of the cell. Antibody compositions that specifically bind to cell-surface-expressed endogenous retrovirus proteins may be used in such diagnostic methods. Overexpression of the endogenous retrovirus proteins can slow cell growth and decrease cell viability.
    Type: Grant
    Filed: January 24, 2014
    Date of Patent: January 30, 2018
    Assignee: REGENTS OF THE UNIVERSITY OF MINNESOTA
    Inventors: Robyn Lynn Leary, Anindya Bagchi, Aaron Lyman Sarver
  • Patent number: 9856312
    Abstract: The present invention relates to a binding molecule having influenza A virus-neutralizing activity derived from a human B cell, and the binding molecule having the influenza A virus-neutralizing activity, according to the present invention, is a binding molecule that is derived from a B cell that is selected from the blood of a patient infected with an influenza A virus, and has neutralizing activity against influenza A viruses, and thus is useful in preventing and treating disease derived from the influenza A virus, and can be useful in diagnosing the influenza A virus by using the binding molecule according to the present invention.
    Type: Grant
    Filed: September 8, 2016
    Date of Patent: January 2, 2018
    Assignee: Celltrion Inc.
    Inventors: Shin Jae Chang, Ki Sung Kwon, Kye Sook Yi, Hyun Joo Lee, Jae Won Jeon, Hwang Keun Jun, Min Seok Chang
  • Patent number: 9833507
    Abstract: The present invention provides novel nucleotides sequences, protein sequences, immunogenic compositions, vaccines, and methods that relate to making and using new porcine parvovirus 5A (PPV5A) that infects, inter alia, domestic swine. The compositions and methods provide for the detection of infections by said new virus, monitoring genetic changes in the viral sequences in wild and domestic animals and herds, and making and using novel vaccines for protecting animals from infection by the virus.
    Type: Grant
    Filed: May 15, 2015
    Date of Patent: December 5, 2017
    Assignee: Boehringer Ingelheim Vetmedica, Inc.
    Inventors: Arun V. Iyer, Dianna M. Murphy Jordan, Abby Rae Patterson, Michael B. Roof, Eric Martin Vaughn, Joseph Gilbert Victoria, Callie Ann Visek
  • Patent number: 9827306
    Abstract: The present invention provides novel nucleotides sequences, protein sequences, immunogenic compositions, vaccines, and methods that relate to making and using new porcine parvovirus 5B (PPV5B) that infects, inter alia, domestic swine. The compositions and methods provide for the detection of infections by said new virus, monitoring genetic changes in the viral sequences in wild and domestic animals and herds, and making and using novel vaccines for protecting animals from infection by the virus.
    Type: Grant
    Filed: May 26, 2015
    Date of Patent: November 28, 2017
    Assignee: Boehringer Ingelheim Vetmedica, Inc.
    Inventors: Arun V. Iyer, Dianna M. Murphy Jordan, Abby Rae Patterson, Michael B. Roof, Eric Martin Vaughn, Joseph Gilbert Victoria, Callie Ann Visek
  • Patent number: 9821051
    Abstract: Compared to an unadjuvanted vaccine, an adjuvanted influenza vaccine can reduce by almost a quarter the risk of hospitalization for respiratory illness (e.g. influenza and pneumonia) in elderly recipients. Thus the invention provides a method for immunizing an elderly subject by administering an adjuvanted influenza vaccine, whereby the subject's risk of hospitalization for respiratory illness (e.g. influenza and pneumonia) is reduced relative to an elderly subject who receives an unadjuvanted influenza vaccine.
    Type: Grant
    Filed: October 21, 2011
    Date of Patent: November 21, 2017
    Assignee: Seqirus UK Limited
    Inventor: Nicola Groth
  • Patent number: 9809801
    Abstract: Provided herein are genetically modified arenaviruses suitable as vaccines against mycobacterial infections. The invention also relates to pharmaceutical compositions and methods for the prevention and treatment of mycobacterial infections. Specifically, provided herein are pharmaceutical compositions, vaccines, and methods of preventing and treating infections in Mycobacterium tuberculosis.
    Type: Grant
    Filed: March 14, 2014
    Date of Patent: November 7, 2017
    Assignee: Université de Genève
    Inventors: Elodie Anne Françoise Belnoue, Stéphanie Gabrielle Darbre Abdelrahman, Arun Thomas Kamath, Paul Lambert, Claire-Anne Siegrist-Julliard, Daniel David Pinschewer
  • Patent number: 9809639
    Abstract: Materials and methods for use of constrained cohydration agents in the purification of biological materials such as antibodies, viruses, cells, and cellular organelles in connection with convective chromatography, fluidized bed or co-precipitation applications.
    Type: Grant
    Filed: June 1, 2012
    Date of Patent: November 7, 2017
    Assignee: AGENCY FOR SCIENCE, TECHNOLOGY AND RESEARCH
    Inventor: Peter Stanley Gagnon
  • Patent number: 9809644
    Abstract: Antibodies against influenza hemagglutinin, compositions containing the antibodies, and methods of using the antibodies are provided herein.
    Type: Grant
    Filed: July 21, 2014
    Date of Patent: November 7, 2017
    Assignee: iBio Inc.
    Inventors: Vidadi Yusibov, Vadim Mett, Jessica Chichester, Lauren Goldschmidt
  • Patent number: 9801936
    Abstract: This invention provides a method of attenuating porcine pseudorabies virus, which can effectively and reproducibly attenuate porcine pseudorabies virus. The attenuated strain of porcine pseudorabies virus by use of said method can provide effective immunization for pigs.
    Type: Grant
    Filed: July 19, 2016
    Date of Patent: October 31, 2017
    Assignee: PULIKE BIOLOGICAL ENGINEERING, INC.
    Inventors: Kegong Tian, Feifei Tan, Jinzhong Sun, Xuke Zhang
  • Patent number: 9795667
    Abstract: This invention provides a method of attenuating porcine pseudorabies virus, which can effectively and reproducibly attenuate porcine pseudorabies virus. The attenuated strain of porcine pseudorabies virus by use of said method can provide effective immunization for pigs.
    Type: Grant
    Filed: July 6, 2015
    Date of Patent: October 24, 2017
    Assignee: PULIKE BIOLOGICAL ENGINEERING, INC.
    Inventors: Kegong Tian, Feifei Tan, Jinzhong Sun, Xuke Zhang
  • Patent number: 9796996
    Abstract: The invention provides methods and means for distinguishing FECV and FIPV, and methods and means for determining whether FIPV is present in a sample. Further provided are primers and probes for detecting FIPV specific nucleic acid sequences encoding a spike protein, antibodies for detecting a FIPV, and an immunogenic composition and use thereof for eliciting an immune response against a feline coronavirus, preferably a FIPV.
    Type: Grant
    Filed: January 18, 2011
    Date of Patent: October 24, 2017
    Assignee: UNIVERSITEIT UTRECHT HOLDING B.V.
    Inventors: Petrus Josephus Marie Rottier, Hui-wen Chang, Herman F. Egberink
  • Patent number: 9789129
    Abstract: Compositions and methods for treating immune cells and activating immune responses are disclosed. The compositions comprise one or more optically active chiral cationic lipids.
    Type: Grant
    Filed: April 14, 2009
    Date of Patent: October 17, 2017
    Assignee: PDS Biotechnology Corporation
    Inventors: Elizabeth Ann Vasievich, Weihsu Claire Chen, Kenya Toney Johnson, Gregory Conn, Frank Bedu-Addo, Leaf Huang
  • Patent number: 9790472
    Abstract: Adeno-associated virus rh.10 sequences, vectors containing same, and methods of use are provided.
    Type: Grant
    Filed: October 3, 2012
    Date of Patent: October 17, 2017
    Assignee: The Trustees of the University of Pennsylvania
    Inventors: Guangping Gao, James M. Wilson, Mauricio R. Alvira
  • Patent number: 9790276
    Abstract: Disclosed herein are glycan-modified anti-CD4 monoclonal antibodies with N-linked glycans attached to the variable region. Expression vectors and cell lines useful for the production of such antibodies, and use of such antibodies for HIV prevention and therapy are also disclosed.
    Type: Grant
    Filed: December 18, 2013
    Date of Patent: October 17, 2017
    Assignee: THE ROCKEFELLER UNIVERSITY
    Inventors: Ruijiang Song, David D. Ho
  • Patent number: 9770501
    Abstract: The invention relates to a novel porcine circovirus type 2 (PCV2) strain. The invention also relates to immunogenic compositions containing the novel PCV2 strain, PCV2 test kits, and applications of the novel PCV2 strain.
    Type: Grant
    Filed: July 2, 2015
    Date of Patent: September 26, 2017
    Assignee: SBC VIRBAC LIMITED.
    Inventors: Tsun-Yung Kuo, Hsu-Chung Gabriel Chen, Chung-Chin Wu, Han-Ting Chen
  • Patent number: 9739773
    Abstract: A host antigen-specific antibody testing system and method. The a ternary complex of the antigen, a ligand-bound anti-host IgM, and a non-host anti-antigen IgG detector conjugate selectively form a quaternary complex with host antibodies, wherein the host antibodies and IgG compete for the antigen, and the anti-host IgM binds the host antibodies. The quaternary complex is retained by an immobilized IgM ligand binding agent, and any residual ternary complex is retained by a later encountered immobilized anti-non-host IgG. If sufficient host antibodies have a high affinity for the antigen, the complex is detected at the quaternary complex detection region based on the presence of the detector, and if there are insufficient high affinity host antibodies, the ternary complex migrates past the quaternary complex detection region and is retained and detected at a control region.
    Type: Grant
    Filed: February 17, 2015
    Date of Patent: August 22, 2017
    Inventor: David Gordon Bermudes
  • Patent number: 9732144
    Abstract: Provided herein are methods and compositions relating to Infectious Bursal Disease Virus (IBDV), and vaccines for treatment and prevention thereof.
    Type: Grant
    Filed: July 5, 2013
    Date of Patent: August 15, 2017
    Assignee: Ohio State Innovation Foundation
    Inventor: Daral John Jackwood